Multiple Sclerosis

Neurodegenerative disorders, including Multiple Sclerosis (MS), are heterogenous disorders which affect the myelin sheath of the central nervous system (CNS). Magnetic Resonance Imaging (MRI) provides a non-invasive method for studying …

Multiple sclerosis (MS) is a chronic, degenerative, and often progressive disease of the central nervous system that can affect multiple parts of the body and result in various symptoms including mobility restrictions, fatigue, pain, depression …

Multiple sclerosis (MS) is characterized by progressive neuroinflammation and neurodegeneration from disease onset that, if left untreated, can result in the accumulation of irreversible neurological disability. Early intervention with …

It is increasingly recognized that cognitive symptoms are a common sequelae of relapsing-remitting multiple sclerosis and are associated with adverse functional consequences. However, estimates of cognitive impairment (CIm) prevalence vary widely.

Primary infection by the varicella-zoster virus leads to childhood varicella (chickenpox) in the majority of the population. The virus remains dormant in the dorsal root ganglia, and can be reactivated later in life, causing herpes zoster (HZ) [ 1 …

Multiple sclerosis (MS) is the most frequent demyelinating and neurodegenerative disease of the central nervous system in young adults [ 1 ]. Due to the unpredictable nature of symptoms in MS in terms of their frequency, severity, and trajectory …

Ocrelizumab (OCR) is a humanized monoclonal antibody that selectively targets CD20+ B cells. It is approved for the treatment of relapsing multiple sclerosis (MS) and primary progressive MS [ 1 , 2 ]. In the pivotal phase 3 trials of OCR (OPERA I …

Multiple sclerosis (MS) is a chronic inflammatory, demyelinating and degenerative CNS disease [ 1 ]. Pathological changes are fuelled by the activation of circulating and CNS resident immune cells [ 2 ]. T, B and natural killer lymphocytes …